Inventiva (IVA) Stock Price, News & Analysis

Company Overview

Inventiva (NASDAQ: IVA) is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapies for the treatment of metabolic, inflammatory, and fibrotic diseases. The company’s core expertise lies in the modulation of nuclear receptors and signaling pathways that regulate fibrosis, inflammation and metabolic dysfunction. Inventiva’s scientific platform integrates medicinal chemistry, in vitro and in vivo pharmacology, and translational sciences to advance a diversified pipeline of therapeutic candidates.

The company’s lead asset, lanifibranor (IVA337), is a pan-PPAR agonist in Phase III development for nonalcoholic steatohepatitis (NASH) and has demonstrated anti-inflammatory and anti-fibrotic effects in preclinical and clinical studies. In addition to lanifibranor, Inventiva is advancing IVA337-related programs and novel small molecules targeting rare diseases such as fibrodysplasia ossificans progressiva (FOP). The pipeline is supported by proprietary chemistry and pharmacology capabilities that enable the optimization of drug candidates with improved efficacy and safety profiles.

Headquartered in Daix, France, Inventiva conducts clinical development activities across Europe and North America. The company collaborates with academic institutions, contract research organizations and strategic partners to support clinical trial conduct and regulatory interactions. Inventiva’s integrated research and development infrastructure includes laboratories in Dijon and a U.S. subsidiary to facilitate patient recruitment and regulatory filings in the United States.

Founded in 2012 as a spin-off from French academic research, Inventiva has built a management team with extensive experience in drug discovery and clinical development. Philippe Luscan, Pharm.D., serves as Chief Executive Officer and has been instrumental in steering the company through its initial public offerings on Euronext Paris and Nasdaq. Under his leadership, Inventiva continues to pursue innovative therapies aimed at addressing significant unmet medical needs in chronic and rare diseases.

Key Stats

• Today's Range: $4.67 to $4.96
• 50-Day Range: $4.77 to $6.09
• 52-Week Range: $2.85 to $7.98
• Volume: 358,168 shs
• Average Volume: 227,237 shs
• Market Capitalization: $834.98 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $16.56
• Consensus Rating: Buy

Inventiva Stock Analysis - MarketRank™

Inventiva scored higher than 68% of companies evaluated by MarketBeat, and ranked 282nd out of 869 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.0 / 5
• Analyst Rating: Buy

Consensus Rating

Inventiva has received a consensus rating of Buy. The company's average rating score is 3.10, and is based on 3 strong buy ratings, 6 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Inventiva has a consensus price target of $16.56, representing about 320.3% upside from its current price of $3.94.

Amount of Analyst Coverage

Inventiva has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Inventiva are expected to decrease in the coming year, from ($0.79) to ($0.90) per share.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.61% of the float of Inventiva has been sold short.

Short Interest Ratio / Days to Cover

Inventiva has a short interest ratio ("days to cover") of 2.08, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Inventiva has recently decreased by 5.18%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Inventiva does not currently pay a dividend.

Dividend Growth

Inventiva does not have a long track record of dividend growth.

News and Social Media

• Score: 2.9 / 5
• News Sentiment: 0.63

News Sentiment

Inventiva has a news sentiment score of 0.63. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.82 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 6 news articles for Inventiva this week, compared to 3 articles on an average week.

Search Interest

Only 1 people have searched for IVA on MarketBeat in the last 30 days. This is a decrease of -80% compared to the previous 30 days.

MarketBeat Follows

6 people have added Inventiva to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days.

Company Ownership

• Score: 0.9 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Inventiva insiders have not sold or bought any company stock.

Percentage Held by Insiders

32.00% of the stock of Inventiva is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

19.06% of the stock of Inventiva is held by institutions.

Company Calendar

• Last Earnings: 2/15/2026
• Today: 6/02/2026
• Jefferies Global Healthcare Conference 2026: 6/03/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:IVA
• CIK: 1756594
• Web: www.inventivapharma.com
• Phone: 33-3-80-44-75-00
• Fax: N/A
• Employees: 100
• Year Founded: 2011

Price Target and Rating

• Average Price Target for Inventiva: $16.56
• High Price Target: $26.00
• Low Price Target: $11.00
• Potential Upside/Downside: +320.3%
• Consensus Rating: Buy
• Rating Score (0-4): 3.10
• Research Coverage: 10 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.16
• Quick Ratio: 3.16

Sales & Book Value

• Annual Sales: $4.48 million
• Price / Sales: 182.50
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.22) per share
• Price / Book: -17.90

Miscellaneous

• Outstanding Shares: 207,707,000
• Free Float: 141,241,000
• Market Cap: $818.16 million
• Optionable: Not Optionable
• Beta: 0.68